Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Bidkar, A. P.; Wang, S.; Bobba, K. N.; Chan, E.; Bidlingmaier, S.; Egusa, E. A.; Peter, R.; Ali, U.; Meher, N.; Wadhwa, A.; Dhrona, S.; Beckford-Vera, D.; Su, Y.; Tang, R.; Zhang, L.; He, J.; Wilson, D. M.; Aggarwal, R.; VanBrocklin, H. F.; Seo, Y.; Chou, J.; Liu, B.; Flavell, R. R.
Show abstract
Radiopharmaceutical therapy is changing the standard of care in prostate cancer (PCa) and other malignancies. We previously reported high CD46 expression in PCa and developed an antibody-drug conjugate and immunoPET agent based on the YS5 antibody, which targets a tumor-selective CD46 epitope. Here, we present the preparation, preclinical efficacy, and toxicity evaluation of [225Ac]DOTA-YS5, a radioimmunotherapy agent based on the YS5 antibody. Our radiolabeled antibody retains binding efficacy and shows a high tumor to background ratio in PCa xenografts. Furthermore, we show that radiolabeled antibody was able to suppress the growth of cell-derived and patient-derived xenografts, including PSMA-positive and deficient models. Nephrotoxicity, not seen at low radioactive doses, is evident at higher radioactivity dose levels, likely due to redistribution of daughter isotope 213Bi. Overall, this preclinical study confirms that [225Ac]DOTA-YS5 is a highly effective treatment and suggests feasibility for clinical translation of CD46 targeted radioligand therapy in PCa.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.